Saint-Herblain (France), June 4, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024. Valneva will present and meet with global institutional investors to discuss VLA15, the world's leading Lyme Disease vaccine candidate, in Phase 3 development and partnered with Pfizer; the Company's growing commercial business, including ongoing launch plans for IX ...